Stryker Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kevin A. Lobo
- Full Time Employees
- 53,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1941 Stryker Way Portage MI United States of America 49002
- IPO Date
- Mar 17, 1980
- CIK
- 0000310764
- Website
- stryker.com
- Similar Companies
- Business
- Stryker Corporation (NYSE: SYK) develops, manufactures, and markets medical technologies, including orthopedic implants and instruments; surgical equipment and navigation systems; endoscopic and communications products; and patient handling and emergency medical equipment. The company offers its Mako robotic-arm assisted surgery platform for orthopedic procedures; Triathlon and Trident hip and knee systems; Gamma3 and T2 intramedullary nailing systems; and Ceros and Variax distal fixation systems, among other specialized devices for joint reconstruction, trauma and extremities, and spine care. Stryker provides interventional devices, including embolic products and guidewires, along with neurotechnology and spine products such as Vizor vision systems and SurgiCount safety sponges; it also delivers solutions for operating room integration and capital equipment. Founded in 1941 and headquartered in Kalamazoo, Michigan, the company operates globally across the Americas, Europe, Asia-Pacific, and other regions, serving hospitals, ambulatory surgery centers, and healthcare providers in the medtech industry. In recent developments, Stryker completed the acquisition of Artelon AB in September 2024, enhancing its sports medicine portfolio with advanced biomaterials for soft tissue regeneration. The company also acquired Wright Medical Group N.V. in 2022, bolstering its extremity reconstruction offerings, and continues to expand through strategic investments, including a new manufacturing facility in Ireland to support European growth. Additionally, Stryker launched the next-generation Mako Total Knee 2.0 application and advanced its Blue Seal bipolar sealer technology, reflecting ongoing innovation in robotics and surgical efficiency amid robust demand in orthopedics and neurotechnology segments.
Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
Is SYK Overvalued? DCF Says Worth $206
Stryker Launches Pangea Plating System in Europe for Fracture Fixation
Stryker Launches Pangea Plating System and Completes First Case in Europe
Stryker Launches Pangea Plating System and Completes First Case in Europe
BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
AVS, Now Part of Stryker, Enrolls First Patient in First-in-Human Coronary Intravascular Lithotripsy Study
PAHC or SYK: Which Is the Better Value Stock Right Now?
Surgical Robotics Meets AI: Intuitive Surgical, Medtronic, and Stryker Are the Sleeper Plays of the Healthcare Boom
Stryker Corporation (SYK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Is SYK Overvalued? DCF Says Worth $206
Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Stryker declares an $0.88 per share quarterly dividend
Stock Of The Day: Is This The Bottom For Stryker?
Stryker Q1 Earnings & Sales Miss Estimates on Cyber Disruption
Stryker to participate in the Bank of America Securities 2026 Global Healthcare Conference
Stryker Corp (SYK) Q1 2026 Earnings Call Highlights: Navigating Cyber Challenges and Strategic Growth
Stryker Corporation (SYK) Q1 2026 Press Conference Call Transcript
Stryker (SYK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Stryker (SYK) Q1 Earnings and Revenues Lag Estimates